In January of this year, RTI Surgical (RTIX) announced a transformative deal as it was becoming a pure play with its spine business. Unfortunately, accounting irregularities and the impact of COVID-19 forced the company to lower the sales price by approximately 10%, which actually is not that bad, yet continued losses and impact of COVID-19 on the remaining spine business creates continued uncertainty.
While the valuation is low, if we adjust for the massive cash inflow, uncertainty is high, certainly as it is still uncertain what the remaining core business could demonstrate in terms of